RCKT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Rocket Pharmaceuticals Inc (RCKT) is not a strong buy for a beginner, long-term investor at this time. Despite some positive technical indicators and a pre-market price increase, the company's financial performance is weak, with declining net income and EPS. Additionally, analysts have lowered price targets, and there are no significant positive catalysts or trading signals to suggest a strong entry point.
The technical indicators show bullish momentum with the MACD histogram at 0.137 (positively expanding), RSI_6 at 94.516 (overbought), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the stock is overbought, and the next resistance level is at 4.715, close to the pre-market price of 4.76.
The company has $188.9 million in cash and investments, providing a cushion for future growth. Participation in major healthcare conferences enhances visibility. The pre-market price is up 5.08%, showing short-term positive sentiment.
The company's financial performance is weak, with a YoY net income drop of -29.49% and EPS decline of -38.71%. Analysts have lowered the price target to $5, indicating limited upside potential. Biotech stocks face scrutiny due to upcoming FDA decisions, which could increase market volatility.
In Q4 2025, Rocket Pharmaceuticals reported no revenue growth (0% YoY), a net income decline of -29.49% YoY, and an EPS drop of -38.71% YoY. The company remains unprofitable, with no clear signs of financial improvement.
Morgan Stanley recently lowered the price target from $7 to $5 and maintained an Equal Weight rating, reflecting cautious sentiment on the stock's potential.
